Table 1. Tumor antigens resulting from mutations

^aClass II HLA are indicated in blue.
^bFrequency in Caucasians, based on (1) Marsh SGE, Parham P, Barber LD. The HLA Factsbook (Academic Press, 2000) for HLA-A, B, C, and DR, and (2) Colombani J. HLA, Fonctions immunitaires et applications médicales (John Libbey Eurotext, 1993) for HLA-DP and DR.
^cThe residues modified by the mutation are indicated in red.
^dThe mutation affects the HLA gene itself.
^eThe mutation is not located in the region encoding the peptide.
^fLink to GenBank.
^gFrameshift product.
^hThe mutation creates a start codon (ATG) that opens an alternative ORF encoding the antigenic peptide. This peptide is recognized by regulatory T cells (Tregs).

References

Baurain J-F, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG. High frequency of autologous anti-melanoma CTLs directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000; 164: 6057-66. (PMID: 10820291)

Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183: 2501-2508. (PMID: 8676070)

Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous CTL on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999; 59: 5785-5792. (PMID: 10582700)

Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92: 7976-7980. (PMID: 7644523)

Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, Coulie PG. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61: 4078-83. (PMID: 11358829)

Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-75. (PMID: 8095167)

Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999; 162: 1730-1738. (PMID: 9973436)

Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997; 72: 784-790. (PMID: 9311595)

Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood 2007; 109: 2985-8. (PMID: 17119119)

Gueguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, Boon T, Van den Eynde BJ. An antigen recognized by autologous CTL on a human bladder carcinoma. J Immunol 1998; 160: 6188-6194. (PMID: 9637538)

Hogan KT, Eisinger DP, Cupp SB, Lekstrom KJ, Deacon DD, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL, Ross MM. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 1998; 58: 5144-5150. (PMID: 9823325)

Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 2004; 172: 6057-64. (PMID: 15128789)

Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer 2007; 120: 2618-24. (PMID: 17294448)

Karanikas V, Colau D, Baurain J-F, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen E, Weynants P, Boon T, Coulie PG. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001; 61: 3718-24. (PMID: 11325844)

Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis JP, Fitzgerald E, Rosenberg SA. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol 2001; 166: 2871-2877. (PMID: 11160356)

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102: 16013-8. (PMID: 16247014)

Linard B, Bezieau S, Benlalam H, Labarriere N, Guilloux Y, Diez E, Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002; 168: 4802-8 (PMID: 11971032)

Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4+ T lymphocytes. Cancer Res 2003; 63: 6735-43. (PMID: 14583468)

Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia 2002; 16: 2400-7. (PMID: 12454745)

Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997; 186: 785-793. (PMID: 9271594)

Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, Deho P, Squarcina P, Robbins PF, Parmiani G, Castelli C. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003; 170: 6363-70. (PMID: 12794170)

Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J Exp Med 1999; 189: 757-765. (PMID: 10049939)

Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol 2003; 23: 415-23. (PMID: 14601650)

Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185-1192. (PMID: 8642260)

Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun [serial online] 2004; 4: 14. URL: http://www.cancerimmunity.org/v4p14/041015.htm (PMID: 15563124)

Sensi M, Nicolini G, Zanon M, Colombo C, Molla A, Bersani I, Lupetti R, Parmiani G, Anichini A. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8+ T cells with a memory phenotype. Cancer Res 2005; 65: 632-40. (PMID: 15695408)

Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004; 64: 1595-9. (PMID: 14996715)

Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006; 118: 1992-7. (PMID: 16287085)

ten Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88: 3522-3527. (PMID: 8896419)

Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res 2002; 62: 5505-9. (PMID: 12359760)

Vigneron N, Ooms A, Morel S, Degiovanni G, Van den Eynde B. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun [serial online] 2002; 2: 9. URL: http://www.cancerimmunity.org/v2p9/020709.htm (PMID: 12747754)

Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang R-F. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002; 195: 1397-406. (PMID: 12045238)

Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 2005; 174: 2661-70. (PMID: 15728473)

Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 1999a; 189: 1659-1667. (PMID: 10330445)

Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999b; 284: 1351-1354. (PMID: 10334988)

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284. (PMID: 7652577)

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001; 61: 6868-75. (PMID: 11559563)

Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998a; 101: 2290-6. (PMID: 9593785)

Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 1998b; 102: 455-62. (PMID: 9664088)

Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 1999; 54: 153-61. (PMID: 10488742)

Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999; 29: 592-601. (PMID: 10064075)